Acclinate

Market position

The company describes itself as a national, enterprise-level organization and category creator in "representative enrollment intelligence," stating it works with 7 of the top 10 pharmaceutical companies in the US and has supported 50+ clinical trials across 35 therapeutic areas. It frames its position around rising regulatory expectations for sponsor diversity action plans and shifts in direct-to-consumer engagement rules.

Acclinate cites always-on community trust with more than five years of national engagement, exclusive representative data signals, patented predictive AI/ML (e-DICT), real-world behavioral insights and enterprise-scale operations. It contrasts its model with traditional recruitment by embedding engagement and education before enrollment begins and by measuring engagement quality and trust rather than volume-based outreach or enrollment-speed metrics.

Technology

The core technology is e-DICT, a patented AI/ML engine that ingests structured, authenticated signals from the NOWINCLUDED member community and produces predictive outputs: a Participation Probability Index, participation likelihood, behavioral readiness, site readiness and retention risk, demographic forecasting, engagement trend analysis and real-time dashboards. The company also publishes a Site Engagement Index framework for ongoing assessment of site readiness to engage communities, and states its predictive approach estimates likely future behavior rather than only reporting past activity.

Go-to-market

Direct enterprise sales to pharmaceutical sponsors and CROs (demo requests on the website), supported by case studies, eBooks, white papers and impact reports; community acquisition through in-person events, culturally relevant content and local partnerships; and channel-style partnerships such as the HCN Global agreement for Hispanic and Latino reach and a NOWINCLUDED scholarship partnership with Black Baseball Media.

Pharmaceutical and biotech research sponsors, CROs and research site teams, plus commercial/marketing and patient-insights functions within life sciences organizations. Community-side participants are individuals from historically underrepresented populations in the US, including Black communities and, through the HCN Global partnership, Hispanic and Latino communities. Community-based organizations, advocacy groups and health systems serve as partners.

Geography

Headquartered in Birmingham, Alabama, after relocating from Huntsville in 2020, with a widely remote team of 30+ across the United States and Canada. Leadership is distributed across Birmingham and Huntsville, AL; Washington, D.C.; and Tampa, FL. Community engagement and reach are described as national.

History

Acclinate was founded in 2020 by Tiffany Whitlow and Del Smith. The same year, the company moved its corporate headquarters from Huntsville, Alabama, to Birmingham, where it became a tenant of The Denham Building in Parkside. In May 2024 it announced a $7 million Series A round led by Cencora Ventures with participation from Labcorp and Latimer Ventures, intended to scale its impact and enhance the e-DICT platform. By 2025 the company described itself as a national, enterprise-level organization with more than five years of community engagement and a June 2025 partnership with HCN Global to expand clinical research access for Hispanic and Latino communities.

Risks & controversies

The company frames its market environment around rising regulatory scrutiny of direct-to-consumer pharmaceutical engagement and regulatory expectations that sponsors submit diversity action plans, and notes that behavioral data must be collected and analyzed responsibly to respect data-protection standards. Member counts are stated inconsistently across company materials (200,000+ in some places, 250,000+ in others).